Drug or technology
3 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
AUG 11, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental labeling approval for an existing combination product; regulatory action that does not contain clinical trial data or efficacy evidence.
APR 6, 2026 · REGULATORY APPROVAL
U.S. Food and Drug Administration
FDA approval of a fixed-dose combination of dapagliflozin and metformin; this is a regulatory action, not a clinical evidence report, and does not contain trial outcomes or comparative efficacy data.
APR 6, 2026 · REGULATORY APPROVAL
U.S. Food and Drug Administration
FDA approval of a generic fixed-dose combination of dapagliflozin and metformin; this is a regulatory action record that does not report clinical trial data or comparative efficacy.